Homocysteine levels and platelet reactivity in coronary artery disease patients treated with Ticagrelor

ConclusionsAmong patients with ACS, despite the elevated platelet reactivity associated to hyperhomocysteinemia, the DAPT with ticagrelor could overcome such phenomenon, achieving an adequate platelet inhibition in the majority of the patients.
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research